<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00601523</url>
  </required_header>
  <id_info>
    <org_study_id>248.633</org_study_id>
    <secondary_id>2007-004234-16</secondary_id>
    <nct_id>NCT00601523</nct_id>
  </id_info>
  <brief_title>Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).</brief_title>
  <official_title>Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The general aim of this study is to obtain long-term safety and tolerability data on
      pramipexole ER, in daily doses from 0.375mg to 4.5mg once daily (q.d), in patients who have
      previously completed a pramipexole double-blind study in early PD (248.524(NCT00479401) or
      248.636(NCT00558025) trial).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With Adverse Events, Adverse Drug Reactions, Serious Adverse Events</measure>
    <time_frame>80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)</time_frame>
    <description>The aim of this study was to obtain long-term safety and tolerability data on pramipexole ER, in patients who have previously completed a pramipexole double blind study in early PD (248.524 (NCT00479401) or 248.636 (NCT00558025)). Therefore these items were considered as a safety evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS) II+III Total Score: Change From Baseline</measure>
    <time_frame>Open Label (OL) baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)</time_frame>
    <description>UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With UPDRS II+III Response From OL Baseline at Week 80 (Patients From 248.524) or Week 72 (Patients From 248.636)</measure>
    <time_frame>OL Baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)</time_frame>
    <description>A response means an improvement of &gt;=20% from OL baseline. UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS I Total Score: Change From OL Baseline</measure>
    <time_frame>OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)</time_frame>
    <description>UPDRS I ranging from 0 (normal) to 16 (severe), measures Mentation, Behavior and Mood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS II Total Score: Change From OL Baseline</measure>
    <time_frame>OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)</time_frame>
    <description>UPDRS II ranging from 0 (normal) to 52 (severe), measures activity of daily living.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS III Total Score: Change From OL Baseline</measure>
    <time_frame>OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)</time_frame>
    <description>UPDRS III ranging from 0 (normal) to 108 (severe) measures motor symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response in Clinical Global Impression of Improvement (CGI-I)</measure>
    <time_frame>OL Baseline and week 32 (patients from 248.524) or week 24 (patients from 248.636)</time_frame>
    <description>Clinicians evaluation in a rating scale of 7 steps, 1 meaning very much improved to 7 meaning very much worse. For patients previously treated with Placebo, all patients with at least &quot;much improved&quot; were considered as responders. For patients previously treated with Pramipexole ER or Immediate Release (IR), all patients with no change to very much improved were considered as responders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response in Patient Global Impression of Improvement (PGI-I)</measure>
    <time_frame>OL Baseline and week 32 (patients from 248.524) or week 24 (patients from 248.636)</time_frame>
    <description>Patient rated evaluation of the PD symptoms on a rating scale of 7 steps, 1 meaning very much better to 7 meaning very much worse. For patients previously treated with Placebo, all patients with at least &quot;much better&quot; were considered as responders. For patients previously treated with pramipexole (PPX) ER or IR, all patients with no change to very much better were considered as responders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson Fatigue Scale (PFS-16) : Change From OL Baseline</measure>
    <time_frame>OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)</time_frame>
    <description>PFS-16 ranging from 16 (better perceived health status) to 80 (severe symptoms of the disease) measuring aspects of fatigue that are relevant to patients with PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Introducing L-Dopa Medication in OL Trial</measure>
    <time_frame>80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)</time_frame>
    <description>Number of patients requiring Levodopa supplementation during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>L-Dopa Dose: Change From OL Baseline</measure>
    <time_frame>OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)</time_frame>
    <description>Change from open-label baseline in Levodopa dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pramipexole Doses Respectively After 80 Weeks Compared to Pramipexole Doses at Week 8 for Previously 248.524 Patients and After 72 Weeks Compared to Pramipexole Doses at Week 0 for Previously 248.636 Patients</measure>
    <time_frame>Week 8 and week 80 (patients from 248.524) or week 0 and week 72 (patients from 248.636)</time_frame>
    <description>Change from open-label baseline in Levodopa dose over the final 72 weeks of open-label assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Preference Regarding Treatment Dosing</measure>
    <time_frame>80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)</time_frame>
    <description>Patients were surveyed on their preference for Once Daily dosing versus Three Times Daily dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Rating of Convenience of Treatment Dosing</measure>
    <time_frame>80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)</time_frame>
    <description>Patients were surveyed on the convenience of Once Daily dosing versus Three Times Daily dosing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">511</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Pramipexole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient to receive Pramipexole ER 0.375-4.5 mg tabl form daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole</intervention_name>
    <description>ER 0.375-4,5 mg</description>
    <arm_group_label>Pramipexole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Completion of the double-blind trial 248.524 or 248.636

          2. Male or female patient with early idiopathic Parkinson´s disease (PD), and with a
             Modified Hoehn and Yahr stage of I to III.

          3. Patient willing and able to comply with scheduled visits, treatment plan, laboratory
             tests and other study procedures.

          4. Signed informed consent obtained before any study procedures are carried out (in
             accordance with International Conference on Harmonisation (ICH) - Good Clinical
             Practice (GCP) guidelines and local legislation).

        Exclusion criteria:

          1. Patients prematurely withdrawn from the double-blind trials 248.524 or 248.636.

          2. Atypical parkinsonian syndromes due to drugs,metabolic disorders, encephalitis or
             degenerative diseases.

          3. Any psychiatric disorder according to Diagnostic and Statistical Manual of Mental
             Disorders, fourth edition (DSM-IV) criteria that could prevent compliance or
             completion of the study and/or put the patient at risk if he/she takes part in the
             study.4.History of psychosis, except history of drug induced hallucinations.

        5. Clinically significant electrocardiogram (ECG) abnormalities at baseline. 6.Clinically
        significant hypotension 7.Malignant melanoma or history of previously treated malignant
        melanoma. 8.Any other clinically significant disease, that could put the patient at risk or
        could prevent compliance or completion of the study. 9. Pregnancy or breast-feeding.

        10. Sexually active female of childbearing potential not using a medically approved method
        of birth control for at least one month prior to the baseline and throughout the study.11
        Serum levels of aspartate aminotransferase (AST) (SGOT), alanine aminotransferase (ALT)
        (SGPT), alkaline phosphatase or bilirubin &gt; 2 upper limit of normal (ULN) at baseline 12.
        Patients with a creatinine clearance &lt; 50 mL/min (estimated by the Cockcroft and Gault
        formula). 13. Motor complications under levodopa therapy (e.g. on-off phenomena,
        dyskinesia) at baseline.

        14. Any medication (including intra-muscular formulations) with central dopaminergic
        antagonist activity within 4 weeks prior to the baseline visit. 15.Any of the following
        drugs within 4 weeks prior to baseline: methylphenidate, cinnarizine, amphetamines. 16.
        Flunarizine within 3 months prior to baseline.

        17. Known hypersensitivity to pramipexole or its excipients. 18. Drug abuse (including
        alcohol), according to investigator´s judgement, within 2 years prior to baseline.

        19. Participation in investigational drug studies other than trials 248.524 and 248.636 or
        use of other investigational drug within one month or five times the half-life of the
        investigational drug prior to baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>248.633.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.01018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.01016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.01013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.01008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.01010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.01012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.01005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.01009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.43004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pardubice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rychnov nad Kneznou</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.35803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyvinkää</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.35802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aix en Provence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3303B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aix en Provence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3303C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aix en Provence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3309A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3309B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3305B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3313A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dijon cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Evreux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3308A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3308B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3308C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3308D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3308E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3302B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3302C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier cédex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3306B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3306C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3306D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3306F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3312A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3312B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3311A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3311B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3301C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse Cedex 7</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3301B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3301D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3301F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.3301G Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Achim bei Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin-Steglitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.49018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.49019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.49016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gera</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.49017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.49012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.49013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.49015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Unterhaching</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.36007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eger</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.36005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Györ</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.36008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sopron</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.36006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.91002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.91009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Karnataka</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.91005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.91007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.91004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.91011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.81010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aomori, Aomori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.81001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bunkyo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.81005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fuchu, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.81011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fujisawa, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.81013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.81015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iwamizawa,Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.81003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kodaira, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.81014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.81009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morioka, Iwate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.81008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okayama, Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.81006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ota-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.81004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sagamihara, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.81007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shimogyo-ku, Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.81012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shiroishi, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.81002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takamatsu, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.60004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuala Terengganu</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Geldrop</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helmond</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.31006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sittard-geleen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.07002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.07003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.07006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.42103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dubnica nad Vahom</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.42101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trnava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.88603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.88605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.88601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.88602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lvov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnytzya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.633.38006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zaporozhye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Japan</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
  </removed_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2008</study_first_submitted>
  <study_first_submitted_qc>January 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <results_first_submitted>June 6, 2011</results_first_submitted>
  <results_first_submitted_qc>July 27, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 25, 2011</results_first_posted>
  <last_update_submitted>June 3, 2014</last_update_submitted>
  <last_update_submitted_qc>June 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients From 248.524</title>
          <description>Pramipexole ER 0.375-4.5 mg. Stratified cohort of patients who had previously completed 248.524 (NCT00479401) and previously received Pramipexole Extended Release (PPX ER), Pramipexole Immediate Release (PPX IR), or Placebo.</description>
        </group>
        <group group_id="P2">
          <title>Patients From 248.636</title>
          <description>Pramipexole ER 0.375-4.5 mg. Stratified cohort of patients who had previously completed 248.636 (NCT00558025) and previously received Pramipexole Extended Release (PPX ER), Pramipexole Immediate Release (PPX IR), or Placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="368"/>
                <participants group_id="P2" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="291"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set, all patients randomized and received treatment</population>
      <group_list>
        <group group_id="B1">
          <title>Patients From 248.524</title>
          <description>Patients who had previously completed 248.524 (NCT00479401)</description>
        </group>
        <group group_id="B2">
          <title>Patients From 248.636</title>
          <description>Patients who had previously completed 248.636 (NCT00558025)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="368"/>
            <count group_id="B2" value="143"/>
            <count group_id="B3" value="511"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="9.2"/>
                    <measurement group_id="B2" value="64.0" spread="9.0"/>
                    <measurement group_id="B3" value="62.7" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Unified Parkinson's Disease Rating Scale (UPDRS) II+III Total Score: Change From Baseline</title>
        <description>UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms</description>
        <time_frame>Open Label (OL) baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)</time_frame>
        <population>Patients from Full Analysis Set (FAS included all patients who received at least one dose of study medication and had at least one post-baseline efficacy assessment) and who had values for UPDRS II+III at week 80 (patients from 248.524) or at week 72 (patients from 248.636)</population>
        <group_list>
          <group group_id="O1">
            <title>Patients From 248.524</title>
            <description>Patients who had previously completed 248.524 (NCT00479401)</description>
          </group>
          <group group_id="O2">
            <title>Patients From 248.636</title>
            <description>Patients who had previously completed 248.636 (NCT00558025)</description>
          </group>
        </group_list>
        <measure>
          <title>Unified Parkinson's Disease Rating Scale (UPDRS) II+III Total Score: Change From Baseline</title>
          <description>UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms</description>
          <population>Patients from Full Analysis Set (FAS included all patients who received at least one dose of study medication and had at least one post-baseline efficacy assessment) and who had values for UPDRS II+III at week 80 (patients from 248.524) or at week 72 (patients from 248.636)</population>
          <units>Units of scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="9.5"/>
                    <measurement group_id="O2" value="1.5" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With UPDRS II+III Response From OL Baseline at Week 80 (Patients From 248.524) or Week 72 (Patients From 248.636)</title>
        <description>A response means an improvement of &gt;=20% from OL baseline. UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms</description>
        <time_frame>OL Baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)</time_frame>
        <population>Patients from Full Analysis Set (FAS included all patients who received at least one dose of study medication and had at least one post-baseline efficacy assessment) and who had values for UPDRS II+III at week 80 (patients from 248.524) or at week 72 (patients from 248.636)</population>
        <group_list>
          <group group_id="O1">
            <title>Patients From 248.524</title>
            <description>Patients who had previously completed 248.524 (NCT00479401)</description>
          </group>
          <group group_id="O2">
            <title>Patients From 248.636</title>
            <description>Patients who had previously completed 248.636 (NCT00558025)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With UPDRS II+III Response From OL Baseline at Week 80 (Patients From 248.524) or Week 72 (Patients From 248.636)</title>
          <description>A response means an improvement of &gt;=20% from OL baseline. UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms</description>
          <population>Patients from Full Analysis Set (FAS included all patients who received at least one dose of study medication and had at least one post-baseline efficacy assessment) and who had values for UPDRS II+III at week 80 (patients from 248.524) or at week 72 (patients from 248.636)</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UPDRS I Total Score: Change From OL Baseline</title>
        <description>UPDRS I ranging from 0 (normal) to 16 (severe), measures Mentation, Behavior and Mood</description>
        <time_frame>OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)</time_frame>
        <population>Patients from FAS and who had values for UPDRS I at week 80 (patients from 248.524) or at week 72 (patients from 248.636)</population>
        <group_list>
          <group group_id="O1">
            <title>Patients From 248.524</title>
            <description>Patients who had previously completed 248.524 (NCT00479401)</description>
          </group>
          <group group_id="O2">
            <title>Patients From 248.636</title>
            <description>Patients who had previously completed 248.636 (NCT00558025)</description>
          </group>
        </group_list>
        <measure>
          <title>UPDRS I Total Score: Change From OL Baseline</title>
          <description>UPDRS I ranging from 0 (normal) to 16 (severe), measures Mentation, Behavior and Mood</description>
          <population>Patients from FAS and who had values for UPDRS I at week 80 (patients from 248.524) or at week 72 (patients from 248.636)</population>
          <units>Units of scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.0"/>
                    <measurement group_id="O2" value="0.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UPDRS II Total Score: Change From OL Baseline</title>
        <description>UPDRS II ranging from 0 (normal) to 52 (severe), measures activity of daily living.</description>
        <time_frame>OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)</time_frame>
        <population>Patients from FAS and who had values for UPDRS II at week 80 (patients from 248.524) or at week 72 (patients from 248.636)</population>
        <group_list>
          <group group_id="O1">
            <title>Patients From 248.524</title>
            <description>Patients who had previously completed 248.524 (NCT00479401)</description>
          </group>
          <group group_id="O2">
            <title>Patients From 248.636</title>
            <description>Patients who had previously completed 248.636 (NCT00558025)</description>
          </group>
        </group_list>
        <measure>
          <title>UPDRS II Total Score: Change From OL Baseline</title>
          <description>UPDRS II ranging from 0 (normal) to 52 (severe), measures activity of daily living.</description>
          <population>Patients from FAS and who had values for UPDRS II at week 80 (patients from 248.524) or at week 72 (patients from 248.636)</population>
          <units>Units of scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="3.2"/>
                    <measurement group_id="O2" value="0.6" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UPDRS III Total Score: Change From OL Baseline</title>
        <description>UPDRS III ranging from 0 (normal) to 108 (severe) measures motor symptoms</description>
        <time_frame>OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)</time_frame>
        <population>Patients from FAS and who had values for UPDRS III at week 80 (patients from 248.524) or at week 72 (patients from 248.636)</population>
        <group_list>
          <group group_id="O1">
            <title>Patients From 248.524</title>
            <description>Patients who had previously completed 248.524 (NCT00479401)</description>
          </group>
          <group group_id="O2">
            <title>Patients From 248.636</title>
            <description>Patients who had previously completed 248.636 (NCT00558025)</description>
          </group>
        </group_list>
        <measure>
          <title>UPDRS III Total Score: Change From OL Baseline</title>
          <description>UPDRS III ranging from 0 (normal) to 108 (severe) measures motor symptoms</description>
          <population>Patients from FAS and who had values for UPDRS III at week 80 (patients from 248.524) or at week 72 (patients from 248.636)</population>
          <units>Units of scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="7.2"/>
                    <measurement group_id="O2" value="0.9" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response in Clinical Global Impression of Improvement (CGI-I)</title>
        <description>Clinicians evaluation in a rating scale of 7 steps, 1 meaning very much improved to 7 meaning very much worse. For patients previously treated with Placebo, all patients with at least &quot;much improved&quot; were considered as responders. For patients previously treated with Pramipexole ER or Immediate Release (IR), all patients with no change to very much improved were considered as responders</description>
        <time_frame>OL Baseline and week 32 (patients from 248.524) or week 24 (patients from 248.636)</time_frame>
        <population>Patients from FAS and who had values for for CGI-I at week 32 (patients from 248.524) or at week 24 (patients from 248.636)</population>
        <group_list>
          <group group_id="O1">
            <title>Patients From 248.524</title>
            <description>Patients who had previously completed 248.524 (NCT00479401)</description>
          </group>
          <group group_id="O2">
            <title>Patients From 248.636</title>
            <description>Patients who had previously completed 248.636 (NCT00558025)</description>
          </group>
        </group_list>
        <measure>
          <title>Response in Clinical Global Impression of Improvement (CGI-I)</title>
          <description>Clinicians evaluation in a rating scale of 7 steps, 1 meaning very much improved to 7 meaning very much worse. For patients previously treated with Placebo, all patients with at least &quot;much improved&quot; were considered as responders. For patients previously treated with Pramipexole ER or Immediate Release (IR), all patients with no change to very much improved were considered as responders</description>
          <population>Patients from FAS and who had values for for CGI-I at week 32 (patients from 248.524) or at week 24 (patients from 248.636)</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response in Patient Global Impression of Improvement (PGI-I)</title>
        <description>Patient rated evaluation of the PD symptoms on a rating scale of 7 steps, 1 meaning very much better to 7 meaning very much worse. For patients previously treated with Placebo, all patients with at least &quot;much better&quot; were considered as responders. For patients previously treated with pramipexole (PPX) ER or IR, all patients with no change to very much better were considered as responders</description>
        <time_frame>OL Baseline and week 32 (patients from 248.524) or week 24 (patients from 248.636)</time_frame>
        <population>Patients from FAS and who had values for for PGI-I at week 32 (patients from 248.524) or at week 24 (patients from 248.636)</population>
        <group_list>
          <group group_id="O1">
            <title>Patients From 248.524</title>
            <description>Patients who had previously completed 248.524 (NCT00479401)</description>
          </group>
          <group group_id="O2">
            <title>Patients From 248.636</title>
            <description>Patients who had previously completed 248.636 (NCT00558025)</description>
          </group>
        </group_list>
        <measure>
          <title>Response in Patient Global Impression of Improvement (PGI-I)</title>
          <description>Patient rated evaluation of the PD symptoms on a rating scale of 7 steps, 1 meaning very much better to 7 meaning very much worse. For patients previously treated with Placebo, all patients with at least &quot;much better&quot; were considered as responders. For patients previously treated with pramipexole (PPX) ER or IR, all patients with no change to very much better were considered as responders</description>
          <population>Patients from FAS and who had values for for PGI-I at week 32 (patients from 248.524) or at week 24 (patients from 248.636)</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parkinson Fatigue Scale (PFS-16) : Change From OL Baseline</title>
        <description>PFS-16 ranging from 16 (better perceived health status) to 80 (severe symptoms of the disease) measuring aspects of fatigue that are relevant to patients with PD.</description>
        <time_frame>OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)</time_frame>
        <population>Patients from FAS and who had values for PFS-16 at week 80 (patients from 248.524) or at week 72 (patients from 248.636)</population>
        <group_list>
          <group group_id="O1">
            <title>Patients From 248.524</title>
            <description>Patients who had previously completed 248.524 (NCT00479401)</description>
          </group>
          <group group_id="O2">
            <title>Patients From 248.636</title>
            <description>Patients who had previously completed 248.636 (NCT00558025)</description>
          </group>
        </group_list>
        <measure>
          <title>Parkinson Fatigue Scale (PFS-16) : Change From OL Baseline</title>
          <description>PFS-16 ranging from 16 (better perceived health status) to 80 (severe symptoms of the disease) measuring aspects of fatigue that are relevant to patients with PD.</description>
          <population>Patients from FAS and who had values for PFS-16 at week 80 (patients from 248.524) or at week 72 (patients from 248.636)</population>
          <units>Units of scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="12.5"/>
                    <measurement group_id="O2" value="2.2" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Introducing L-Dopa Medication in OL Trial</title>
        <description>Number of patients requiring Levodopa supplementation during the study</description>
        <time_frame>80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)</time_frame>
        <population>Patients from FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Patients From 248.524</title>
            <description>Patients who had previously completed 248.524 (NCT00479401)</description>
          </group>
          <group group_id="O2">
            <title>Patients From 248.636</title>
            <description>Patients who had previously completed 248.636 (NCT00558025)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Introducing L-Dopa Medication in OL Trial</title>
          <description>Number of patients requiring Levodopa supplementation during the study</description>
          <population>Patients from FAS</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>L-Dopa Dose: Change From OL Baseline</title>
        <description>Change from open-label baseline in Levodopa dose</description>
        <time_frame>OL baseline and week 80 (patients from 248.524) or week 72 (patients from 248.636)</time_frame>
        <population>Patients from FAS and with L-Dopa at OL baseline and at week 80 (patients from 248.524) or week 72 (patients from 248.636)</population>
        <group_list>
          <group group_id="O1">
            <title>Patients From 248.524</title>
            <description>Patients who had previously completed 248.524 (NCT00479401)</description>
          </group>
          <group group_id="O2">
            <title>Patients From 248.636</title>
            <description>Patients who had previously completed 248.636 (NCT00558025)</description>
          </group>
        </group_list>
        <measure>
          <title>L-Dopa Dose: Change From OL Baseline</title>
          <description>Change from open-label baseline in Levodopa dose</description>
          <population>Patients from FAS and with L-Dopa at OL baseline and at week 80 (patients from 248.524) or week 72 (patients from 248.636)</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pramipexole Doses Respectively After 80 Weeks Compared to Pramipexole Doses at Week 8 for Previously 248.524 Patients and After 72 Weeks Compared to Pramipexole Doses at Week 0 for Previously 248.636 Patients</title>
        <description>Change from open-label baseline in Levodopa dose over the final 72 weeks of open-label assessment</description>
        <time_frame>Week 8 and week 80 (patients from 248.524) or week 0 and week 72 (patients from 248.636)</time_frame>
        <population>Patients from Treated Set (defined as all patients who were dispensed study drug and were documented to have at least one dose of investigational treatment) and treated until week 80 (patients from 248.524) or week 72 (patients from 248.636)</population>
        <group_list>
          <group group_id="O1">
            <title>Patients From 248.524</title>
            <description>Patients who had previously completed 248.524 (NCT00479401)</description>
          </group>
          <group group_id="O2">
            <title>Patients From 248.636</title>
            <description>Patients who had previously completed 248.636 (NCT00558025)</description>
          </group>
        </group_list>
        <measure>
          <title>Pramipexole Doses Respectively After 80 Weeks Compared to Pramipexole Doses at Week 8 for Previously 248.524 Patients and After 72 Weeks Compared to Pramipexole Doses at Week 0 for Previously 248.636 Patients</title>
          <description>Change from open-label baseline in Levodopa dose over the final 72 weeks of open-label assessment</description>
          <population>Patients from Treated Set (defined as all patients who were dispensed study drug and were documented to have at least one dose of investigational treatment) and treated until week 80 (patients from 248.524) or week 72 (patients from 248.636)</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="339"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Adverse Events, Adverse Drug Reactions, Serious Adverse Events</title>
        <description>The aim of this study was to obtain long-term safety and tolerability data on pramipexole ER, in patients who have previously completed a pramipexole double blind study in early PD (248.524 (NCT00479401) or 248.636 (NCT00558025)). Therefore these items were considered as a safety evaluation</description>
        <time_frame>80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)</time_frame>
        <population>Patients from Treated Set (defined as all patients who were dispensed study drug and were documented to have at least one dose of investigational treatment)</population>
        <group_list>
          <group group_id="O1">
            <title>Patients From 248.524</title>
            <description>Patients who had previously completed 248.524 (NCT00479401)</description>
          </group>
          <group group_id="O2">
            <title>Patients From 248.636</title>
            <description>Patients who had previously completed 248.636 (NCT00558025)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Adverse Events, Adverse Drug Reactions, Serious Adverse Events</title>
          <description>The aim of this study was to obtain long-term safety and tolerability data on pramipexole ER, in patients who have previously completed a pramipexole double blind study in early PD (248.524 (NCT00479401) or 248.636 (NCT00558025)). Therefore these items were considered as a safety evaluation</description>
          <population>Patients from Treated Set (defined as all patients who were dispensed study drug and were documented to have at least one dose of investigational treatment)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of Patients with Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.5"/>
                    <measurement group_id="O2" value="76.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Patients with Adverse Drug Reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7"/>
                    <measurement group_id="O2" value="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Patients with Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4"/>
                    <measurement group_id="O2" value="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Preference Regarding Treatment Dosing</title>
        <description>Patients were surveyed on their preference for Once Daily dosing versus Three Times Daily dosing</description>
        <time_frame>80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)</time_frame>
        <population>Patients from Full Analysis Set (FAS included all patients who received at least one dose of study medication and had at least one post-baseline efficacy assessment)</population>
        <group_list>
          <group group_id="O1">
            <title>Patients From 248.524</title>
            <description>Patients who had previously completed 248.524 (NCT00479401)</description>
          </group>
          <group group_id="O2">
            <title>Patients From 248.636</title>
            <description>Patients who had previously completed 248.636 (NCT00558025)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Preference Regarding Treatment Dosing</title>
          <description>Patients were surveyed on their preference for Once Daily dosing versus Three Times Daily dosing</description>
          <population>Patients from Full Analysis Set (FAS included all patients who received at least one dose of study medication and had at least one post-baseline efficacy assessment)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prefer Once Daily dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prefer 3 Times Daily dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Preference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Rating of Convenience of Treatment Dosing</title>
        <description>Patients were surveyed on the convenience of Once Daily dosing versus Three Times Daily dosing</description>
        <time_frame>80 weeks (patients from 248.524) or 72 weeks (patients from 248.636)</time_frame>
        <population>Patients from Full Analysis Set (FAS included all patients who received at least one dose of study medication and had at least one post-baseline efficacy assessment)</population>
        <group_list>
          <group group_id="O1">
            <title>Patients From 248.524</title>
            <description>Patients who had previously completed 248.524 (NCT00479401)</description>
          </group>
          <group group_id="O2">
            <title>Patients From 248.636</title>
            <description>Patients who had previously completed 248.636 (NCT00558025)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Rating of Convenience of Treatment Dosing</title>
          <description>Patients were surveyed on the convenience of Once Daily dosing versus Three Times Daily dosing</description>
          <population>Patients from Full Analysis Set (FAS included all patients who received at least one dose of study medication and had at least one post-baseline efficacy assessment)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="367"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Once Daily much more convenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Once Daily more convenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Times Daily much more convenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Times Daily more convenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No difference in preference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 80 weeks for patients from 248.524, Up to 72 weeks for patients from 248.636</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Patients From 248.524</title>
          <description>Patients who had previously completed 248.524 (NCT00479401)</description>
        </group>
        <group group_id="E2">
          <title>Patients From 248.636</title>
          <description>Patients who had previously completed 248.636 (NCT00558025)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Myocardial rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Borrelia infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Prostatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arthroscopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Cervical root pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>On and off phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Sleep attacks</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Hydroureter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

